HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

January 17, 2024

https://www.globenewswire.com/news-release/2024/01/16/2809721/0/en/HOOKIPA-Pharma-Appoints-Mark-Winderlich-as-Chief-Development-Officer-to-Lead-Clinical-Research-and-Development-Organization.html

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024 (‘effective date’). Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.

Read more at globenewswire.com

Related news for (HOOK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.